# Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

> **NCT03685344** · PHASE1 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 13 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** Loncastuximab Tesirine and Durvalumab

## Key facts

- **NCT ID:** NCT03685344
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-04
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy.
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685344, "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03685344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*